Ionis Pharmaceuticals (IONS)
$37.11
0.25 (0.68%)
IONS Stock Quote Delayed 30 Minutes
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
5.26B
PE Ratio
-185.55
EPS
-0.2
Volume (Avg. Vol.)
858,713
Day's Range
$36.95 - $37.85
52-Week Range
$25.04 - $43.21
Dividend & Yield
N/A (N/A)
IONS Stock Predictions, Articles, and Ionis Pharmaceuticals News
Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal
Akcea Therapeutics (AKCA) stock is flying high on Monday following news of a $250 million deal with Pfizer (NYSE:PFE) for licensing rights.
Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.
Why Every Investor Should Hold Shares of Biogen Stock
Biogen reported solid study results for its Alzheimer's study and followed up with a solid quarterly earnings report. BIIB stock is a clear core holding for investors.
10 Ionis Pharmaceuticals Inc Earnings Highlights
Ionis Pharmaceuticals (IONS) released its earnings report for the first quarter of 2018 on Friday and 'InvestorPlace' has some highlights from it.
9 More Stocks Still Growing Faster Than Amazon
If you're looking for growth, Amazon.com isn't your only investment choice. These names are on a tear as well, and could be worthy additions to your portfolio.
4 Scorching Hot Momentum Stocks to Beat the Market
This screen will help you to get into momentum stocks that are storming ahead. Highlighted stocks include: IONS, OSB and SKX.
Ionis Pharmaceuticals Inc (IONS) Shares Fall on Drug Safety Concerns
Ionis Pharmaceuticals (IONS) stock was down on Monday on safety concerns for its drug inotersen following results from a phase 3 study.
Ionis Pharmaceuticals Inc (IONS) Stock Dips on Goldman Sachs Downgrade
Ionis Pharmaceuticals (IONS) shares were plummeting Friday as the stock received a downgrade from Goldman Sachs following its disastrous Monday.
Hottest Manufacturing Stocks Now – MBRX ZYNE SID ONVO
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
37 Biotechnology Stocks to Sell Now
This week, the overall grades of 37 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
52 Biotechnology Stocks to Sell Now
The overall ratings of 52 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Biggest Movers in Manufacturing Stocks Now – SCMP EBIO RVNC AGTC
The following stocks were moving the Manufacturing sector today.
Hottest Manufacturing Stocks Now – CEMP IONS CC WATT
The following stocks were moving the Manufacturing sector today.
27 Biotechnology Stocks to Sell Now
This week, 27 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Why Ionis Pharmaceuticals Inc (IONS), Newell Brands Inc (NWL) and Trina Solar Limited (ADR) (TSL) Are 3 of Today’s Best Stocks
It was a slow start to the week and the month of August, but IONS, NWL and TSL delivered some Monday excitement.
Why Biogen Inc (BIIB) Stock Is Soaring Today
Biogen Inc (BIIB) stock was up on Monday following positive results from its Phase 3 trial of its nusinersen treatment for SMA.
